吉貝爾(688566.SH)擬對經營範圍進行變更
格隆匯 7 月 15日丨吉貝爾(688566.SH)公佈,根據公司生產經營需要及登記機關關於經營範圍規範表述的有關要求,公司擬對經營範圍進行變更,變更後的經營範圍如下:
許可項目:藥品生產(依法須經批准的項目,經相關部門批准後方可開展經營活動,具體經營項目以審批結果為準)
一般項目:生物化工技術產品研發;技術服務、技術開發、技術諮詢、技術交流、技術轉讓、技術推廣;非居住房地產租賃;土地使用權租賃;道路貨物運輸(不含危險貨物);普通貨物倉儲服務(不含危險化學品等需許可審批的項目);倉儲設備租賃服務(依法須經批准的項目,經相關部門批準後方可開展經營活動)
公司經營範圍以登記機關核准登記為準。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.